Details of the Drug Combination

General Information of Drug Combination (ID: DCD01T0)

Drug Combination Name
Amonafide SY-1425
Indication
Disease Entry Status REF
Colon carcinoma Investigative [1]
Component Drugs Amonafide   DMAH59S SY-1425   DMH8UF0
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: KM12
Zero Interaction Potency (ZIP) Score: 0.49
Bliss Independence Score: 2.48
Loewe Additivity Score: 9.07
LHighest Single Agent (HSA) Score: 10.95

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Amonafide
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [3]
Myelodysplastic syndrome 2A37 Phase 1 [3]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Glioma DC9H3DO SF-539 Investigative [4]
Melanoma DC4ULPP MALME-3M Investigative [4]
Papillary renal cell carcinoma DC9IN3P ACHN Investigative [4]
Plasma cell myeloma DCV7YQD RPMI-8226 Investigative [4]
Carcinoma DCXL28C MCF7 Investigative [1]
Invasive ductal carcinoma DCNRE8R HS 578T Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.